Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada

Targeted therapy is a new cancer treatment approach, involving drugs that particularly target speci c proteins in cancer cells, such as receptor tyrosine kinases (RTKs) which are involved in promoting growth and proliferation, Therefore inhibiting these proteins could impede cancer progression. An understanding of RTKs and the relevant signaling cascades, has enabled the development of many targeted drug therapies employing RTK inhibitors (RTKIs) that have entered clinical applications. Here we discuss RTK structures, activation mechanisms and functions. Moreover, we cover the potential effects of combination drug therapy (including chemotherapy drugs with one RTKI or multiple RTKIs) especially for drug resistant cancers.

show abstract

Receptor tyrosine kinase inhibitors in cancer

Ebrahimi

Fardi

Ghaderi

et al. 2023

Cell. Mol. Life Sci.

View full text Add to dashboard Cite

show abstract

Afatinib best value for money as first-line treatment for EGFR-mutated non-small-cell lung cancer

2021

PharmacoEcon Outcomes News

View full text Add to dashboard Cite

Assessing Patient Risk, Benefit, and Outcomes in Drug Development: Insights From Afatinib Clinical Trials Across Diverse Cancer Indications

Hunter Hall,

Wright,

Hughes

et al. 2024

Clinical Therapeutics

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada

Cited by 7 publications

References 50 publications

Receptor tyrosine kinase inhibitors in cancer

Receptor tyrosine kinase inhibitors in cancer

Afatinib best value for money as first-line treatment for EGFR-mutated non-small-cell lung cancer

Assessing Patient Risk, Benefit, and Outcomes in Drug Development: Insights From Afatinib Clinical Trials Across Diverse Cancer Indications

Contact Info

Product

Resources

About